Chenzhou Jingui Silver Industry Co Ltd

Hunan Silver released its first-half 2026 report, achieving operating revenue of 8.719 billion yuan, up 92.54% year on year; net profit attributable to shareholders of the listed company was 168 million yuan, up 170.34% year on year. The company's second-quarter net profit was 13 million yuan, and first-quarter net profit was 156 million yuan. Based on this, second-quarter net profit fell 91% quarter on quarter.

In early trading on July 6, the three major A-share indices opened collectively higher, with the Shanghai Composite Index up 0.30%, the Shenzhen Component Index up 0.65%, and the ChiNext Index up 0.57%. Precious metals concept stocks rose rapidly, with Hunan Silver, Shanjin International, and Chifeng Gold among the top gainers. Nonferrous metals concept stocks were active, with Baiyin Nonferrous, Huanghe Whirlwind, and Yongshan Lithium hitting limit up. The innovative drug sector was also active, with Sanyuan Gene and Hotgen Biotech surging over 10%, after the National Medical Products Administration sought public comment on optimizing the review and approval of cell and gene therapy drugs, proposing to include eligible drugs in a 30-day review channel. JPMorgan expects gold to remain range-bound in the short term before rebounding, with an average price of 4,300 US dollars per ounce in the third quarter of 2026 and 4,500 US dollars per ounce in the fourth quarter, maintaining a long-term bullish view.